Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

8001 Background: Panobinostat (PAN; LBH589) is a potent pan-deacetylase inhibitor (pan-DACi) that disrupts aggresome and HSP90 function via inhibition of HDAC6, promoting cytotoxic misfolded protei...